Drug Profile

Cysteine hydrochloride injection - Exela Pharma Sciences

Alternative Names: ELCYS

Latest Information Update: 22 Dec 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Exela Pharma Sciences
Class Amino acids; Neutral amino acids; Sulfhydryl compounds; Sulfur amino acids
Mechanism of Action Cysteine replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Liver disorders; Nutrition disorders

Most Recent Events

12 May 2020 Cysteine hydrochloride injection receives priority review from the US FDA before April 2019
07 May 2020 Exela Pharma Sciences receives Paragraph IV certificate from Eton Pharmaceuticals challenging the validity of its patents for Cysteine hydrochloride injection

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com